Early aggressive treatment approaches for multiple sclerosis
A Simpson, EM Mowry, SD Newsome - Current treatment options in …, 2021 - Springer
Purpose of review This review presents a comprehensive analysis of the current high-
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
efficacy disease-modifying therapies (DMTs) available for treatment of multiple sclerosis …
Spatial and temporal distribution of the prevalence of unemployment and early retirement in people with multiple sclerosis: A systematic review with meta-analysis
Background We aimed to summarise the prevalence of unemployment and early retirement
among people with MS and analyze data according to a spatio-temporal perspective …
among people with MS and analyze data according to a spatio-temporal perspective …
Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best
strategy to delay irreversible neurological damage and progression of multiple sclerosis …
strategy to delay irreversible neurological damage and progression of multiple sclerosis …
Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with multiple sclerosis
J Maurino, ML Martínez-Ginés… - Multiple sclerosis and …, 2020 - Elsevier
Abstract Introduction In Multiple Sclerosis (MS), withdrawal from employment is a critical
problem. This study explores relationships between disease characteristics, work difficulties …
problem. This study explores relationships between disease characteristics, work difficulties …
Change in multiple sclerosis prevalence over time in Australia 2010–2017 utilising disease-modifying therapy prescription data
JA Campbell, S Simpson Jr, H Ahmad… - Multiple Sclerosis …, 2020 - journals.sagepub.com
Objective: Determine the prevalence of multiple sclerosis (MS) in Australia in 2017 using MS-
specific disease-modifying therapy (DMT) prescription data and estimate the change in …
specific disease-modifying therapy (DMT) prescription data and estimate the change in …
Economic burden of multiple sclerosis in a population with low physical disability
JM García-Domínguez, J Maurino, ML Martínez-Ginés… - BMC public health, 2019 - Springer
Background In multiple sclerosis (MS), half of affected people are unemployed within 10
years of diagnosis. The aim of this study was to assess the economic impact of MS in adult …
years of diagnosis. The aim of this study was to assess the economic impact of MS in adult …
Predictors of change in employment status and associations with quality of life: a prospective international study of people with multiple sclerosis
Purpose This prospective international study aimed to assess the changes in employment,
and predictors thereof, and associated change in mental health quality of life in people with …
and predictors thereof, and associated change in mental health quality of life in people with …
Investigation of the health economic analysis of informal care for people living with a chronic neurological disease: A systematic review and meta-analysis of the …
TG Adal, I van der Mei, BV Taylor, B de Graaff… - Social Science & …, 2024 - Elsevier
Multiple sclerosis (MS) is a chronic neurological disease that causes substantial health
economic impacts, however, the cost of informal care for MS is often excluded from health …
economic impacts, however, the cost of informal care for MS is often excluded from health …
Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia
Background Multiple sclerosis (MS) is an inflammatory, neurodegenerative disease of the
central nervous system which results in disability over time and reduced quality of life. To …
central nervous system which results in disability over time and reduced quality of life. To …
Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the …
Objective To estimate differences in treatment costs and health outcomes between non-
myeloablative hematopoietic stem cell transplantation (HSCT) and disease-modifying …
myeloablative hematopoietic stem cell transplantation (HSCT) and disease-modifying …